Lexicon Pharmaceuticals (LXRX) Expected to Announce Earnings on Thursday

Posted by on May 5th, 2026

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) will likely be posting its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Lexicon Pharmaceuticals to post earnings of ($0.04) per share and revenue of $9.79 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last issued its quarterly earnings data on Thursday, March 5th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 41.94% and a negative net margin of 101.08%.The business had revenue of $5.49 million for the quarter, compared to analysts’ expectations of $3.14 million. On average, analysts expect Lexicon Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lexicon Pharmaceuticals Stock Performance

Shares of Lexicon Pharmaceuticals stock traded down $0.02 during trading hours on Tuesday, hitting $1.59. 700,916 shares of the company’s stock traded hands, compared to its average volume of 2,592,876. Lexicon Pharmaceuticals has a 12-month low of $0.51 and a 12-month high of $1.95. The stock has a market capitalization of $671.53 million, a price-to-earnings ratio of -11.32 and a beta of 0.97. The company has a fifty day simple moving average of $1.65 and a 200-day simple moving average of $1.45. The company has a debt-to-equity ratio of 0.46, a current ratio of 4.88 and a quick ratio of 4.87.

Insider Activity

In other Lexicon Pharmaceuticals news, Director Raymond Debbane bought 100,000 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was purchased at an average cost of $1.47 per share, with a total value of $147,000.00. Following the transaction, the director directly owned 1,904,186 shares in the company, valued at $2,799,153.42. This trade represents a 5.54% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders acquired 252,000 shares of company stock worth $369,980. Company insiders own 14.00% of the company’s stock.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several large investors have recently added to or reduced their stakes in LXRX. CIBC Bancorp USA Inc. purchased a new stake in Lexicon Pharmaceuticals in the 3rd quarter worth about $3,240,000. Millennium Management LLC increased its holdings in Lexicon Pharmaceuticals by 133.1% in the 3rd quarter. Millennium Management LLC now owns 3,830,660 shares of the biopharmaceutical company’s stock worth $5,171,000 after acquiring an additional 2,187,396 shares during the last quarter. Marshall Wace LLP purchased a new stake in Lexicon Pharmaceuticals in the 4th quarter worth about $1,452,000. AQR Capital Management LLC purchased a new stake in Lexicon Pharmaceuticals in the 1st quarter worth about $541,000. Finally, Goldman Sachs Group Inc. increased its holdings in Lexicon Pharmaceuticals by 1,452.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 921,204 shares of the biopharmaceutical company’s stock worth $1,059,000 after acquiring an additional 861,857 shares during the last quarter. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Citigroup raised their target price on Lexicon Pharmaceuticals from $2.10 to $2.30 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Lexicon Pharmaceuticals in a research report on Monday, March 23rd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $4.15.

View Our Latest Analysis on LXRX

About Lexicon Pharmaceuticals

(Get Free Report)

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.

Featured Stories

Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.